171 results
8-K
EX-99.1
TLPH
Talphera Inc.
6 Mar 24
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
- will evaluate the safety and efficacy of Niyad to support a Premarket Approval application (PMA) projected to be submitted to the FDA by the end
8-K
EX-10.1
TLPH
Talphera Inc.
22 Jan 24
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
5:12pm
, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case of (i), (ii
8-K
EX-10.2
TLPH
Talphera Inc.
22 Jan 24
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
5:12pm
, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment
8-K
EX-3.2
TLPH
Talphera Inc.
9 Jan 24
Talphera will begin trading on Nasdaq under the trading symbol “TLPH” effective January 10
9:17am
at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly
8-K
EX-99.1
qarjhu
8 Nov 23
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
4u562q fk
31 Jul 23
Other Events
9:47pm
8-K
EX-10.1
t79e7s5
21 Jul 23
Entry into a Material Definitive Agreement
8:15am
8-K
EX-99.1
uiko x1b344828zbts
7 Apr 23
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
3:37pm
8-K
EX-99.1
i7a56b
30 Mar 23
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
4:10pm
424B5
ys1v4gsq0a8
28 Dec 22
Prospectus supplement for primary offering
5:26pm
424B7
al747ma adb
22 Nov 22
Prospectus with selling stockholder info
4:29pm